These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 14175

  • 1. Reduction of adenylate cyclase activity in lysates of human platelets by the alpha-adrenergic component of epinephrine.
    Jakobs KH, Saur W, Schultz G.
    J Cyclic Nucleotide Res; 1976; 2(6):381-92. PubMed ID: 14175
    [Abstract] [Full Text] [Related]

  • 2. Characterization of the human platelet alpha-adrenergic receptor. Correlation of [3H]dihydroergocryptine binding with aggregation and adenylate cyclase inhibition.
    Alexander RW, Cooper B, Handin RI.
    J Clin Invest; 1978 May; 61(5):1136-44. PubMed ID: 207726
    [Abstract] [Full Text] [Related]

  • 3. Desensitization of epinephrine-initiated platelet aggregation does not alter binding to the alpha 2-adrenergic receptor or receptor coupling to adenylate cyclase.
    Motulsky HJ, Shattil SJ, Ferry N, Rozansky D, Insel PA.
    Mol Pharmacol; 1986 Jan; 29(1):1-6. PubMed ID: 2418346
    [Abstract] [Full Text] [Related]

  • 4. Alpha 2-adrenergic receptor-mediated regulation of adenylate cyclase in the intact human platelet. Evidence for a receptor reserve.
    Lenox RH, Ellis J, Van Riper D, Ehrlich YH.
    Mol Pharmacol; 1985 Jan; 27(1):1-9. PubMed ID: 2981397
    [Abstract] [Full Text] [Related]

  • 5. Activation of adenylate cyclase from purified platelet membranes by prostaglandin E1 and its inhibition by L-epinephrine: mechanistic effects.
    Steer ML, Braun S, Lester HA, Levitzki A.
    J Cyclic Nucleotide Res; 1982 Jan; 8(5):309-22. PubMed ID: 7182416
    [Abstract] [Full Text] [Related]

  • 6. The alpha adrenergic response of Down's syndrome platelets.
    Sheppard JR, Schumacher W, White JG, Jakobs KH, Schultz G.
    J Pharmacol Exp Ther; 1983 Jun; 225(3):584-8. PubMed ID: 6306212
    [Abstract] [Full Text] [Related]

  • 7. [The adenylate cyclase system of human platelets].
    Ferry N, Adnot S, Insel PA, Hanoune J.
    Nouv Rev Fr Hematol (1978); 1983 Jun; 25(6):343-53. PubMed ID: 6141550
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of Ns-stimulated human platelet adenylate cyclase by forskolin.
    Watanabe Y, Jakobs KH.
    Mol Pharmacol; 1986 Mar; 29(3):258-63. PubMed ID: 3005833
    [Abstract] [Full Text] [Related]

  • 9. The effect of alpha and beta adrenergic receptor stimulation on the adenylate cyclase activity of human adipocytes.
    Burns TW, Langley PE.
    J Cyclic Nucleotide Res; 1975 Mar; 1(5):321-8. PubMed ID: 1225939
    [Abstract] [Full Text] [Related]

  • 10. Receptors, adenylate cyclase, depression, and lithium.
    Belmaker RH.
    Biol Psychiatry; 1981 Apr; 16(4):333-50. PubMed ID: 6261845
    [Abstract] [Full Text] [Related]

  • 11. Parallel observation of the occupancy of the alpha 2-adrenergic receptor in intact platelets and its ability to inhibit the adenylate cyclase.
    Macfarlane DE, Stump DC.
    Mol Pharmacol; 1982 Nov; 22(3):574-9. PubMed ID: 6296652
    [Abstract] [Full Text] [Related]

  • 12. Characterization of adenylate cyclase activity in bovine and human corneal epithelium.
    Walkenbach RJ, LeGrand RD, Barr RE.
    Invest Ophthalmol Vis Sci; 1980 Sep; 19(9):1080-6. PubMed ID: 6106005
    [Abstract] [Full Text] [Related]

  • 13. Metal and metal-ATP interactions with human platelet adenylate cyclase: effects of alpha adrenergic inhibition.
    Jakobs KH, Saur W, Schultz G.
    Mol Pharmacol; 1978 Nov; 14(6):1073-8. PubMed ID: 32476
    [No Abstract] [Full Text] [Related]

  • 14. Mode of action of ticlopidine in inhibition of platelet aggregation in the rat.
    Ashida SI, Abiko Y.
    Thromb Haemost; 1979 Apr 23; 41(2):436-49. PubMed ID: 224522
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of the stimulatory effect of adrenaline and prostaglandin E1 on the human fat cell adenylate cyclase by adenosine.
    Kather H, Simon B.
    Horm Metab Res; 1980 Apr 23; 12(4):169-72. PubMed ID: 7390397
    [Abstract] [Full Text] [Related]

  • 16. Alpha-adrenergic inhibition of renal cortical adenylate cyclase.
    Woodcock EA, Johnston CI, Olsson CA.
    J Cyclic Nucleotide Res; 1980 Apr 23; 6(4):261-9. PubMed ID: 6110680
    [Abstract] [Full Text] [Related]

  • 17. Hormone-sensitive fat cell adenylate cyclase in the rat. Influences of growth, cell size, and aging.
    Cooper B, Gregerman RI.
    J Clin Invest; 1976 Jan 23; 57(1):161-8. PubMed ID: 173740
    [Abstract] [Full Text] [Related]

  • 18. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
    Maurice DH, Haslam RJ.
    Mol Pharmacol; 1990 May 23; 37(5):671-81. PubMed ID: 2160060
    [Abstract] [Full Text] [Related]

  • 19. Interactions of agonists with platelet alpha 2-adrenergic receptors.
    Hoffman BB, Michel T, Brenneman TB, Lefkowitz RJ.
    Endocrinology; 1982 Mar 23; 110(3):926-32. PubMed ID: 6120077
    [Abstract] [Full Text] [Related]

  • 20. Phorbol ester-induced augmentation and inhibition of epinephrine-stimulated adenylate cyclase in S49 lymphoma cells.
    Johnson JA, Goka TJ, Clark RB.
    J Cyclic Nucleotide Protein Phosphor Res; 1986 Mar 23; 11(3):199-215. PubMed ID: 3020100
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.